Single engineered tRNA targets majority of nonsense-caused inherited retinal diseases
A preprint describes an anticodon-edited tRNA that achieves up to 86% readthrough across 13 clinically relevant Arg-to-stop variants, offering a gene-agnostic strategy for a prevalent subclass of inherited retinal disease.
Researchers have described an anticodon-edited (ACE) tRNA — designated V3 — engineered to suppress premature termination codons arising from arginine-to-stop (Arg>Ter) nonsense variants, the most common single subclass of premature stop codons in inherited retinal diseases (IRDs). The preprint, posted to bioRxiv, combines a large-scale survey of published genetic data from more than 37,500 IRD patients with functional tRNA engineering.
Nonsense variants are estimated to underlie approximately 18% of all inherited retinal disease cases. Among premature stop codons in this group, Arg>Ter transitions account for roughly 35%, making them a natural focal point for a shared therapeutic approach. The ACE-tRNA V3 construct achieved readthrough efficiencies of up to 86% across the 13 clinically relevant variants tested in laboratory models, and restored native localisation of the PRCD protein, a well-characterised IRD-associated gene product.
The approach is described as gene-agnostic — the same tRNA molecule could in principle address multiple disease-causing variants across different IRD genes, rather than requiring a separate therapy for each variant. The authors frame this as a potential response to the longstanding challenge that the extreme genetic heterogeneity of IRDs has made variant-by-variant drug development economically and practically difficult.
This work is a preprint and has not yet completed peer review. The retinal-delivery, safety, and in vivo efficacy data that would be required to evaluate any future clinical development are not yet reported.
Plain-language version
For patients, families, and general readers. Educational only — not medical advice.
Inherited retinal diseases (IRDs) are a group of conditions caused by faults in the genes needed for the retina — the light-sensitive tissue at the back of the eye — to work properly. Some of these faults create what scientists call a "stop signal" too early in the genetic instructions, preventing the cell from making a working protein.
Researchers have engineered a tiny molecule called a transfer RNA (tRNA) that can read through one common type of these early stop signals — those caused by changes affecting a building block called arginine. In laboratory tests, a single version of this molecule worked across 13 different disease-causing variants in several different IRD genes, restoring production of a protein that is lost in some forms of retinal disease.
This research is at an early stage and has not yet been reviewed by independent scientists (it is what is called a preprint). Much more research would be needed before anything like this could be considered in a clinical setting.
This is an educational summary, not medical advice. If anything here raises questions for you, please speak with your GP or a clinical professional.
Sources
Read the original reporting — these are the public sources this summary draws from.
-
Primary sourcePreprint bioRxiv (Cold Spring Harbor Laboratory) · 2026-07-23Single anticodon-edited tRNA therapy targeting highly prevalent Arg>Ter premature termination codons causing inherited retinal diseases